Kuzmits R, Kokoschka E M, Micksche M, Ludwig H, Flener R
Oncology. 1985;42 Suppl 1:26-32. doi: 10.1159/000226081.
There is as yet no effective treatment for renal cell carcinoma and metastasizing malignant melanoma. This fact, coupled with in vitro investigations showing growth inhibitory or cytotoxic effects of interferon (IFN) on renal cell carcinoma and melanoma cell lines, led to phase II clinical trials with recombinant (r) IFN-alpha 2C and rIFN-gamma. So far 8 patients with renal cell carcinoma have been treated with IFN-alpha 2C and 3 patients with rIFN-gamma. There has been one complete response to IFN-alpha 2C, two mixed responses and one partial response. One patient on rIFN-gamma has stable disease and the other 2 have progressed. Eleven patients with metastasizing malignant melanoma were treated with IFN-alpha 2C. One patient achieved a complete remission and 3 others had stable disease which later progressed in 2 of them. Side-effects were reversible.
目前尚无针对肾细胞癌和转移性恶性黑色素瘤的有效治疗方法。这一事实，再加上体外研究表明干扰素（IFN）对肾细胞癌和黑色素瘤细胞系具有生长抑制或细胞毒性作用，促使开展了使用重组（r）IFN-α2C和rIFN-γ的II期临床试验。到目前为止，已有8例肾细胞癌患者接受了IFN-α2C治疗，3例患者接受了rIFN-γ治疗。IFN-α2C治疗有1例完全缓解，2例混合反应和1例部分缓解。1例接受rIFN-γ治疗的患者病情稳定，另外2例病情进展。11例转移性恶性黑色素瘤患者接受了IFN-α2C治疗。1例患者实现完全缓解，另外3例病情稳定，但其中2例后来病情进展。副作用是可逆的。
